ArticleNPJ science of food2025
In vitro and in vivo investigation of the capacity of mulberroside A to inhibit senescence.
Article in NPJ science of food, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Mulberroside A attenuates HMolecular medicine reports · 2026Article
- Mulberroside A Alleviates Scopolamine-Induced Cognitive Deficits by Suppressing Neuroinflammation and Oxidative Stress via theBiology · 2026Article
- An integrated annotation strategy for the phytochemical characterization of Xie-Bai-San decoction based on UPLC-Q Exactive Orbitrap HRMS, multi-database screening, and feature-based molecular networking.Frontiers in chemistry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Mulberroside A, naturally existent from the mulberry plant, is known for its diverse biological activities. Our research indicates that mulberroside A may possess significant anti-aging effects. We assessed its anti-aging properties using naturally aging animal models and by inducing senescence in human-derived endothelial cells and mouse-derived endothelial cells through treatment with angiotensin II. We found that mulberroside A promotes the proliferation of HMEC-1 and bEnd.3 endothelial cells, while significantly reducing the levels of senescence biomarkers p16, p21, and Rb in both these endothelial cell types and in the hippocampus, kidney, spleen and liver of naturally aging animals. Additionally, mulberroside A was found to mitigate telomerase depletion in the blood of naturally aging animals, enhance the body's resistance ability to oxidative stress, and inhibit the overexpression of inflammatory factors in vivo.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.